Research Evidence / Overview of Studies for Calcibronat
Evidence for Symptomatic Support in Nervous Excitability
The evidence base for Calcibronat (Calcium Bromolactobionate) primarily consists of historical clinical data and studies that are non-comparative in nature. Research has explored how symptoms may change over time in individuals experiencing mild nervous excitation, irritability, and related sleep disturbances. These studies monitored patient-reported outcomes describing perceived discomfort related to these conditions, which are characterized by fluctuating or episodic manifestations. Reported findings in the older literature describe patterns observed in the studies over short time frames. However, official regulatory findings from national health agencies have indicated that the available data provides limited insight into definitive therapeutic value, reflecting a regulatory classification of Insufficient Medical Benefit based on the available data.
Source of Evidence and Study Quality
The quality of evidence for this medication is characterized as low by regulatory bodies. The research base is lacking in modern, high-quality, placebo-controlled Randomized Controlled Trials (RCTs), which are the gold standard for establishing a drug's effectiveness in trials. The evidence quality varies across studies, with much of the current authorization relying on older documentation. Comparative evidence is lacking to evaluate how the medication was studied in comparison to placebo or other common treatments.
Duration of Study and Long-Term Information
The studies for Calcibronat were evaluated during periods of increased symptom activity, and research examined short-term symptom changes over defined time intervals that supported only short-term symptomatic administration. Typical follow-up durations were limited, reflecting the intended temporary use of the medication. Consequently, there is limited information for long-term outcomes or the durability of any observed symptomatic changes. Long-term effects are not well characterized by the existing research, and they are not fully established over months or years.
Research in Specific Populations
Research was evaluated in general populations of adults experiencing the target symptoms. Additionally, studies monitored children in a specific weight range experiencing nervous symptoms. Data for certain groups remain insufficient, and findings related to these populations are often documented within the primary study reports. The results apply only to the populations studied and do not provide sufficient evidence to draw conclusions about other groups.
Key Evidence Gaps and Uncertainties
A critical uncertainty in the evidence landscape is the absence of comparative studies. The low rating of medical benefit by authoritative bodies underscores the fact that the current data are still emerging and certainty remains low regarding its defined context of use. Subgroup findings are uncertain, meaning research does not determine whether an individual will respond similarly to the group patterns observed. The evidence highlights what is known—and what is still uncertain—about the medication's evidence profile based on regulatory science.
Key Studies & References
- CALCIBRONAT (bromo-galactogluconate de calcium) - Haute Autorité de Santé (HAS) Transparency Commission Review
- WHO Collaborating Centre for Drug Statistics Methodology: ATC Classification N05CM Other hypnotics and sedatives
